Indoco Remedies Q1 FY27 Earnings Call Summary

Event Participants

Executives

3 Aditi Panandikar (MD), Pramod Ghorpade (CFO), Sundeep Bambolkar (Joint MD)

Analysts

10 Dhruv Sitlani (Leo Capital), Kaustubh Ghugna (Kamana Holdings), Kenil Mehta (Boring AMC), Nirmam Mehta (Unique PMS), Pratik Kothari (Unique PMS), Raghu Ram (BestPals Research), Raja Kumar (RK Investment), Sanjoy (Credent), Sudarshan Padmanabhan (ASK Wealth), Zain (Dolat Capital)

Financials & KPIs

Geographic & Segment Commentary

• Domestic Formulations: Revenue of ₹2,014 million, near-flat YoY. Ranked 33rd in Indian Pharma Market (IQVIA MAT June 2026) with 20th rank in prescription volume (MAT May 2026); field force covers 242,000 doctors. Top 5 brands contribute 42% of portfolio; Cyclopam at ₹196 crore (44% growth since 2022, approaching ₹200 crore mega-brand status); Febrex Plus rebounded to ₹118 crore; mid-size portfolio (SM Fibro, Rexidin-M, Oxipod CV, Dropizin) grew 86% aggregate with Dropizin 3x to ₹14 crore. Four brands rank in top 20 of the stomatological market. Anti-infective and respiratory segments (Febrex Plus, Karvol Plus) de-grew due to delayed monsoons.

• International Formulations: ₹1,451 million (+2.8% YoY), 35% of consolidated revenue. Regulated markets grew 19.3% to ₹1,133 million with US up 62.2% to ₹459 million; Europe grew 2.5% to ₹650 million; South Africa/Australia/NZ at ₹24 million. Emerging markets declined to ₹317 million from ₹461 million on primary-billing timing after an exceptionally strong March, war-related product shortages, and freight cost challenges; secondary demand remains steady with double-digit growth.

• API Business: ₹521 million, +42.4% YoY - the standout performer of the quarter. Provides critical backward integration for the formulations pipeline. Warren AURIC facility has completed audits by top-5 Indian pharmaceutical companies with procurement begun; CEP logged, US FDA expected in 6-7 months.

• OTC / Oral Care (Warren Remedies): Q1 FY27 OTC revenue of ₹34 crore with healthy growth, but marginal loss of ~₹6 crore. Kidodent and Sensodyne KAF performing well; sensitivity segment and overall oral care market expanding. Management expects ~3 years of consistent brand-support investment in this competitive category.

• CRO & Analytical (AnaCipher, IAS): ₹69 million, +36.2% YoY - supporting the high-value filings pipeline.

Company-Specific & Strategic Commentary

• Regulatory Milestones: Baddi Unit I and Goa Plant I successfully cleared Malta Medicines Authority audits; Baddi Unit III received EU GMP certification from the German Health Authority (Berlin); Indoco Stability Center (IAS) at Aurangabad completed a US FDA pre-approval inspection with zero observations. Warren API site CEP logged with US FDA inspection expected in 6-7 months.

• Ophthalmic Divestment: Divestment of the ophthalmic division in India and agreed African territories completed - a deliberate step to sharpen focus on core therapeutic areas with stronger potential. Associated cost exit of ~200 employees reflected in Q1; proceeds partly utilized for debt reduction, balance retained for working capital and potential Indian brand acquisitions.

• Operational Efficiency / Master Manufacturing Plan: Structural cost program delivered 26% fewer manufacturing batches for equivalent or higher output, ~900 operational roles eliminated, larger batch sizes, product-mix rebalancing across sites, automation-driven process time reduction. All plants (Goa I, Baddi I, Baddi III) operating at 70-80% utilization on single shift, allowing output to double without incremental CapEx.

• Domestic Brand Strategy: Focused on scaling mid-size brands into mega brands and deepening specialty prescription share; new product introductions contributing ~₹100 crore at MAT level. Top-10 brand concentration increasingly de-risks portfolio from acute-segment seasonality.

• Warren API Integration: AURIC facility positioned to supply KSMs for conversion at Patalganga and finished APIs for regulated-market formulations - the monetization path for the API investment; customer audits from major Indian players completed successfully.

Guidance & Outlook

Risks & Constraints

Q&A Highlights

US FDA Audit & Approval Timeline

• Question: Any update on the US FDA launch? (Nirmam Mehta, Unique PMS)
• Answer: No update yet; "keeping fingers crossed" for the next couple of months. Management later confirmed the site has been ready for over six months, with repeated FDA assurances that the audit will happen soon, though no date has been given. (Aditi Panandikar)

International Business Performance & Order Book

• Question: International revenue is flat - Europe stagnant and emerging de-growing. Any structural concerns? (Nirmam Mehta, Unique PMS; Kenil Mehta, Boring AMC)
• Answer: Emerging market decline is a one-quarter timing effect - a very strong March primary push followed by expected Q1 normalization; secondary demand is growing double-digit and primaries should rebound in Q2. Europe's dip reflects shipment timing, not demand - the order book exceeds ₹250 crore and international reg business posted a record Q4. Europe and emerging are expected to perform consistently going forward. (Aditi Panandikar)

COGS Inflation & Margin Guidance

• Question: Gross margins took a hit - will this persist? What is the steady-state EBITDA margin? (Nirmam Mehta, Unique PMS; Sudarshan Padmanabhan, ASK Wealth)
• Answer: COGS was impacted by ~200 bps due to war-driven material shortages and price increases; the impact will partly continue into Q2 and normalize by Q3. Management aims for double-digit EBITDA margins, with the last two quarters showing a clear upward trend. Margin improvement will come from operating leverage as utilization rises. (Aditi Panandikar)

Debt, Interest Costs & Use of Divestment Proceeds

• Question: What is the debt position, how does ₹28 crore quarterly interest reconcile with 9% rates, and how will ophthalmic proceeds be used? (Nirmam Mehta; Pratik Kothari, Unique PMS; Kaustubh Ghugna, Kamana Holdings)
• Answer: Total debt is ₹930 crore (LT ₹600 crore + ST ₹325 crore). Quarterly interest of ₹20.5 crore at 9% average, with the balance being actual exchange losses on the euro-denominated loan. Repayment plan: ₹110 crore in FY27 and ₹150 crore in FY28 (₹260 crore over 17-18 months). Ophthalmic proceeds were partly used for debt repayment; the balance is retained as investment for working capital. Future cash may fund Indian brand acquisitions. (Pramod Ghorpade; Aditi Panandikar)

Operational Efficiency & Capacity Utilization

• Question: Are the employee/expense reductions sustainable? What are the plant utilization levels? (Pratik Kothari, Unique PMS; Kenil Mehta, Boring AMC)
• Answer: ~900 operational roles have been eliminated; 26% fewer batches now produce equivalent or higher output. The master manufacturing plan (larger batch sizes, automation, product-mix rebalancing, faster packing) is structurally in place. Capacity utilization: Goa Plant I 70-80%, Baddi I 70-80%, Baddi III 70-75%, all on single shift - can double with demand and no additional CapEx. (Aditi Panandikar)

US/Europe Launch Pipeline

• Question: What is the outlook for US launches, VIGAMOX momentum, and Europe pickup? (Sudarshan Padmanabhan, ASK Wealth)
• Answer: Current US products (brimonidine, dorzolamide, allopurinol, glimepiride, varenicline) are performing well. Oral-solid launches are tied to 2027 patent expiries; early patent expiries expected in Europe next year. Concrete ophthalmic guidance deferred until the US FDA audit completes - VIGAMOX numbers will be discussed once there is clarity. (Aditi Panandikar)

Path to PBT Profitability

• Question: How will operating profit scale above the ~₹250 crore interest-plus-depreciation burden to turn PBT positive? (Kaustubh Ghugna, Kamana Holdings)
• Answer: India and emerging markets are the most profitable segments and growing steadily - they will continue to add operating profit. Europe has reached a scale where efficiency investments will increasingly drop to the operating line. The US is in a high-growth phase and small; it will contribute but not dominate. Management expects operating profitability to scale as volumes absorb fixed costs across all three engines. (Aditi Panandikar)

Warren OTC / Oral Care Business

• Question: What is the current scale, unit economics, and short-to-medium-term outlook for the toothpaste business? (Dhruv Sitlani, Leo Capital)
• Answer: Q1 OTC revenue was ₹34 crore with healthy growth; marginal loss of ~₹6 crore for Warren Remedies overall (API manufacturing + OTC sales). Kidodent and Sensodyne KAF are performing well; the sensitivity segment is growing. Given competitive intensity and the advertising scale of incumbents, ~3 years of consistent brand support is required to build a meaningful portfolio. (Aditi Panandikar)

US FDA Contingency & US Subsidiary Profitability

• Question: If the FDA audit doesn't materialize, are there alternative plans? Is the US subsidiary now profitable? (Kenil Mehta, Boring AMC)
• Answer: Management will not wait indefinitely - it is exploring LATAM and other emerging geographies for sterile products, though Europe alone cannot substitute US scale. The US subsidiary turned positive this quarter after the earlier one-off inventory write-off. Sterile plant operating costs remain high due to 24/7 utilities running under current restrictions, and meaningful upside requires the plant to run at full steam post-audit. (Aditi Panandikar)

Key Takeaway

Indoco Remedies delivered steady Q1 FY27 results with consolidated revenue of ₹4,662 million (+8.2% YoY) and consolidated EBITDA margin of 8.8% (vs 4.1% YoY), driven by API growth (+42.4% to ₹521 million) and US formulations (+62.2% to ₹459 million), while domestic formulations stayed flat at ₹2,014 million on seasonal softness and emerging markets dipped to ₹317 million on primary-billing timing. Structural efficiency gains - 26% fewer manufacturing batches and ~900 fewer operational employees - underpin the double-digit EBITDA margin target. Strategically, the company secured EU GMP certification for Baddi III, a zero-observation US FDA pre-approval inspection at its Aurangabad stability center, and completed the ophthalmic divestment. Management guides to higher single-digit/double-digit India growth, export doubling over 2-3 years, and ₹260 crore debt repayment over 18 months. Key watch points remain the pending US FDA audit at Baddi (now delayed 6+ months), war-driven COGS inflation partially impacting Q2, and Warren's planned 3-year OTC investment phase.